Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DAWN Day One Biopharmaceuticals	$6.99 -3.0%	$6.63	$5.64 ▼ $16.76	$716.50M	-1.26	1.37 million shs	466,649 shs
DNTH Dianthus Therapeutics	$23.53 -3.2%	$19.94	$13.36 ▼ $32.27	$763.47M	1.43	322,876 shs	159,281 shs
PROK ProKidney	$2.37 -1.9%	$2.29	$0.46 ▼ $7.13	$695.97M	1.76	5.63 million shs	636,881 shs
TVGN Tevogen Bio	$0.91 -2.8%	$1.11	$0.26 ▼ $3.09	$179.01M	-0.77	1.41 million shs	393,433 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DAWN Day One Biopharmaceuticals	0.00%	+6.67%	-0.41%	+14.83%	-48.90%
DNTH Dianthus Therapeutics	0.00%	+17.16%	+13.02%	+31.92%	-14.13%
PROK ProKidney	0.00%	+2.12%	-26.75%	+239.15%	+0.84%
TVGN Tevogen Bio	0.00%	-1.25%	-11.66%	-28.52%	+61.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DAWN Day One Biopharmaceuticals	2.2524 of 5 stars	3.6	2.0	2.0	2.5	0.0
DNTH Dianthus Therapeutics	1.161 of 5 stars	3.5	0.0	1.7	0.8	0.0
PROK ProKidney	3.7118 of 5 stars	4.2	4.0	1.7	3.3	0.6
TVGN Tevogen Bio	3.9696 of 5 stars	3.5	3.0	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DAWN Day One Biopharmaceuticals	3.13	Buy	$25.29	262.00% Upside
DNTH Dianthus Therapeutics	3.00	Buy	$54.00	129.49% Upside
PROK ProKidney	2.33	Hold	$6.25	164.27% Upside
TVGN Tevogen Bio	3.00	Buy	$10.00	998.90% Upside

Current Analyst Ratings Breakdown

Latest TVGN, DAWN, PROK, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$34.00 ➝ $42.00
8/18/2025	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$25.00
8/18/2025	PROK ProKidney	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00
8/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DAWN Day One Biopharmaceuticals	$131.16M	5.45	N/A	N/A	$4.99 per share	1.40
DNTH Dianthus Therapeutics	$4.85M	156.03	N/A	N/A	$11.91 per share	1.98
PROK ProKidney	$80K	8,699.65	N/A	N/A	($3.41) per share	-0.69
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	10/29/2025 (Estimated)
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	11/6/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.57	N/A	N/A	N/A	N/A	N/A	-17.11%	11/11/2025 (Estimated)
TVGN Tevogen Bio	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-775.49%	11/10/2025 (Estimated)

Latest TVGN, DAWN, PROK, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	N/A	TVGN Tevogen Bio	-$0.05	-$0.03	+$0.02	-$0.03	N/A	N/A
8/12/2025	Q2 2025	PROK ProKidney	-$0.14	-$0.13	+$0.01	-$0.13	N/A	$0.22 million
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DAWN Day One Biopharmaceuticals	N/A	9.65	9.53
DNTH Dianthus Therapeutics	N/A	13.12	13.12
PROK ProKidney	N/A	11.48	11.48
TVGN Tevogen Bio	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DAWN Day One Biopharmaceuticals	87.95%
DNTH Dianthus Therapeutics	47.53%
PROK ProKidney	51.59%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
DAWN Day One Biopharmaceuticals	6.20%
DNTH Dianthus Therapeutics	8.15%
PROK ProKidney	41.49%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
DNTH Dianthus Therapeutics	80	32.19 million	26.86 million	Optionable
PROK ProKidney	3	294.28 million	172.18 million	Optionable
TVGN Tevogen Bio	3	196.71 million	52.64 million	N/A

TVGN, DAWN, PROK, and DNTH Headlines

Recent News About These Companies

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

1 hour ago | globenewswire.com

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22 at 12:13 AM | markets.businessinsider.com

Tevogen Bio Holdings Inc. Recognized in BINJE's BEST Health Care 2025 for Commitment to Health Equity and Innovation

August 22 at 3:51 PM | quiverquant.comQ

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22 at 3:25 PM | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

August 21, 2025 | marketbeat.com

D. Boral Capital Reiterates Buy Rating for Tevogen Bio (NASDAQ:TVGN)

August 20, 2025 | marketbeat.com

Tevogen finalizes agreement for up to $50M in financing

August 19, 2025 | msn.com

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance ...

August 19, 2025 | bakersfield.comB

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

August 19, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Q2 2025 Financial Results with Reduced Loss from Operations and Focus on Growth Strategy

August 19, 2025 | quiverquant.comQ

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

August 19, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

August 18, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

August 18, 2025 | globenewswire.com

Semper Paratus Acquisition (NASDAQ:TVGN) Stock Price Down 3% - Here's What Happened

August 16, 2025 | marketbeat.com

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

August 14, 2025 | globenewswire.com

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

August 13, 2025 | globenewswire.com

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

August 11, 2025 | globenewswire.com

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

August 11, 2025 | globenewswire.com

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

August 11, 2025 | globenewswire.com

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

August 11, 2025 | globenewswire.com

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

August 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, DAWN, PROK, and DNTH Company Descriptions

Day One Biopharmaceuticals NASDAQ:DAWN

$6.98 -0.22 (-2.99%)

As of 03:35 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Dianthus Therapeutics NASDAQ:DNTH

$23.53 -0.77 (-3.17%)

As of 03:34 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

ProKidney NASDAQ:PROK

$2.37 -0.05 (-1.87%)

As of 03:35 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tevogen Bio NASDAQ:TVGN

$0.91 -0.03 (-2.82%)

As of 03:34 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time